Advertisement

Vertex Pharmaceuticals Inc. (Nasdaq: VRTX) rose 6 percent on Thursday, leading up to a 5 p.m. call with investors regarding its third quarter earnings, after it announced two new partnerships for studies of its potential treatment for hepatitis C.

Advertisement
Advertisement